- Home
- TALKW vs MREO Comparison
TALKW vs MREO Comparison
Compare TALKW & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TALKW | MREO |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United Kingdom |
| Employees | 598 | 39 |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 49.4M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | TALKW | MREO |
|---|---|---|
| Price | $0.00 | $0.32 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 148.9K | ★ 4.2M |
| Earning Date | 02-20-2025 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $181,291,000.00 | $500,000.00 |
| Revenue This Year | N/A | $5,184.20 |
| Revenue Next Year | N/A | $55.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 31.50 | N/A |
| 52 Week Low | $0.00 | $0.20 |
| 52 Week High | $0.10 | $2.94 |
Technical Indicators
Market Signals| Indicator | TALKW | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 38.89 | 56.15 |
| Support Level | N/A | $0.30 |
| Resistance Level | $0.01 | $0.36 |
| Average True Range (ATR) | 0.00 | 0.03 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 1.45 | 49.00 |
Price Performance
Historical ComparisonAbout TALKW Talkspace Inc. Warrant
Talkspace Inc is a virtual behavioral healthcare company offering its members convenient and affordable access to a fully-credentialed network of qualified providers across a wide and growing spectrum of care through virtual psychotherapy and psychiatry. It is a single destination for comprehensive mental health care, including therapy for individuals, couples, and teens, as well as psychiatric treatment and medication management (18+), and self-guided tools and resources. The company's customers include Health insurance plans from commercial and government institutions, and employee assistance programs, Direct-to-Enterprise, and Individual subscribers. The company operates as a single segment.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).